Helsinn Healthcare S.A. et al. v. Fresenius Kabi USA, LLC

I'll research this case thoroughly across multiple sources before drafting.

I'll research this case and its related proceedings. Let me start with several parallel searches.

Let me get the actual docket and the refiled New Jersey action.

Now let me trace the New Jersey refiling and any PTAB proceedings.

Bottom line

This is a seven‑week "placeholder" Hatch‑Waxman/505(b)(2) case. Helsinn and Roche filed a five‑patent complaint in D. Del. on 2015‑10‑13 and voluntarily dismissed it without prejudice on 2015‑12‑01 (docket shows termination 2015‑12‑01; some trackers list 12‑02). Nothing of substance happened in Delaware — no answer, no Rule 12 motion, no transfer/stay motion, no Markman, no discovery orders. The real action was a substantively identical complaint Helsinn filed five days earlier in D.N.J. (No. 3:15‑cv‑07378‑MLC‑DEA), which absorbed both Fresenius and the Exela entities and was steered to Judge Mary L. Cooper, who was already managing the Aloxi® palonosetron litigations. The most consequential legal event for the family of patents at issue came later and elsewhere: the Federal Circuit's and Supreme Court's on‑sale‑bar invalidation of the '724 patent claims in Helsinn v. Teva.

---

1. Filing & initial pleadings

2015‑08‑28 — Fresenius Kabi sends Helsinn a Notice Letter for NDA No. 208109 (a § 505(b)(2) NDA, not an ANDA) seeking approval for generic 0.25 mg/5 mL palonosetron HCl IV solution. The 45‑day § 271(e) window thus expired mid‑October 2015. A separate, earlier Fresenius ANDA (No. 206802) had already generated litigation over the '219 and '094 patents.

2015‑10‑08 — Helsinn Healthcare S.A. and Roche Palo Alto LLC file D.N.J. No. 3:15‑cv‑07378‑MLC‑DEA against Fresenius Kabi USA, LLC and Exela Pharma Sciences, LLC, Exela PharmSci, Inc., and Exela Holdings, Inc., asserting the same five patents: '724, '981, '218, '980, and '905. Assigned to Judge Mary L. Cooper (D.N.J., Trenton), Mag. J. Douglas E. Arpert. This is the operative refiling. (PatentDocs Court Report; docket record)

2015‑10‑13 — Complaint filed in D. Del. No. 1:15‑cv‑00918 against Fresenius alone (D.I. 1; D.I. 4 is the AO‑120 patent report form listing '724, '981, '218, '980, '905). The complaint pleads five § 271(e)(2) counts plus declaratory‑judgment counts under §§ 271(a)–(c). Two pleading features are worth flagging:

• For the '980 and '905 patents, Helsinn did not allege a Paragraph IV certification. It alleged that because Fresenius's NDA 208109 sought approval before expiration of the other Orange Book patents (same expiry), Fresenius "necessarily" sought approval before the '980/'905 expiries and was "required by law" to amend its certification. See Compl. ¶¶ 37–41, 45–49 (complaint text). That is an aggressive, DJ‑style theory rather than a conventional § 271(e)(2) theory.
• The '905 patent issued 2015‑09‑08 — about five weeks before suit — so it post‑dated Fresenius's certification entirely; that is precisely why the "necessarily seeks approval" theory was needed.

Plaintiffs' counsel: Saul Ewing LLP (Charles M. Lizza, William C. Baton) as New Jersey counsel; Paul Hastings LLP (Joseph M. O'Malley, Jr., Eric W. Dittmann, Isaac S. Ashkenazi, Angela C. Ni) for Helsinn; Loeb & Loeb LLP (Mark E. Waddell) for Roche. Morris, Nichols, Arsht & Tunnell (Karen Jacobs) was Delaware counsel. (NJ complaint caption)

Answer/counterclaims. No answer was ever filed in Delaware. Fresenius's answer, affirmative defenses, and counterclaims were filed in the New Jersey action (D.I. 11 there), admitting the patents exist and that Fresenius markets generics in New Jersey while denying infringement and pleading invalidity. (D.I. 11, 3:15‑cv‑07378) Exela appeared through Merchant & Gould (Lee A. Goldberg) with C. Edward Polk, Jr. and Satish Chintapalli admitted pro hac vice in January 2016.

2. Pre‑trial motions of substance

None in Delaware. Because the case was dismissed roughly seven weeks after filing, there was never a motion to dismiss under Rule 12(b)(3)/(b)(6), no § 1404(a) transfer motion, no motion to stay pending IPR, and no summary‑judgment practice. There is also no docket indication Judge Sleet ever held a Rule 16 conference; the case carried the "UNA" (unassigned) designation on the complaint filings, consistent with dismissal before full assignment.

The one non‑frivolous venue/jurisdiction fight in the family was happening on a neighboring track: Judge Cooper's 2016‑04‑05 opinion in Helsinn v. Hospira, No. 3:15‑cv‑02077, rejecting a personal‑jurisdiction and Rule 12(b)(6) challenge brought by Hospira and its marketing subsidiary Worldwide, relying on Acorda for the proposition that an ANDA filing establishes a substantial connection with the forum. (opinion excerpt) That ruling reinforced New Jersey as Helsinn's chosen forum for the Aloxi® generics program and is the implicit backdrop to why the Delaware duplicate was abandoned.

3. Claim construction (Markman)

None in this case. No Markman order, no Janssen/OMG procedure, no claim‑construction hearing in No. 1:15‑cv‑00918. Claim construction affecting these patents came from the D.N.J. Aloxi® track: Judge Cooper's 2015‑04‑22 memorandum opinion construing preamble language in the '219 patent claims (Dkt. 290 in No. 11‑3962), and later constructions on prosecution disclaimer — e.g., the holding that the '724 applicants' amendment replacing "preventing" with "reducing the likelihood of emesis" to overcome an enablement rejection unmistakably disclaimed "preventing," and that under Elkay the disclaimer carries into later‑issued family members using the same limitation. (post‑2018 opinion) Note that this disclaimer ruling cuts directly at the "reducing the likelihood of [CINV]" limitations common to the '724/'981/'218/'980/'905 family — relevant to Fresenius's defense but never reached in the Delaware case.

4. Discovery milestones with strategic significance

None in Delaware. No Rule 26(f) conference, no ESI order, no protective order, no fact or expert discovery occurred before dismissal. The strategic point is the negative: because the Delaware case died pre‑answer, Fresenius never had to produce its NDA 208109, its bioequivalence/stability data, or its formulation records in that forum, and Helsinn never obtained Delaware‑based discovery.

In New Jersey, by contrast,

I'll research the counsel of record for the plaintiffs in this D. Del. case.

Bottom line

This D. Del. action was on the docket for only seven weeks and contains six docket entries (complaint, five exhibits, civil cover sheet/report to Patent Office — CourtListener docket 4220932). There were no motions, no answers, no pro hac vice applications, and no formal "appearance" entries before the plaintiffs voluntarily dismissed on December 1, 2015. So the plaintiffs' counsel roster is defined entirely by (a) the signature block of the complaint (D.I. 1) and (b) the registered Delaware attorney who signed the dismissal. A full pro hac vice roster for the national trial team was never built in this case — it was built in the New Jersey refiling, which I describe separately below.

Counsel of record — plaintiffs Helsinn Healthcare S.A. and Roche Palo Alto LLC

What I could not verify (flagged rather than guessed)

• The 00918 complaint's signature block. The case's RECAP/RPX copies of D.I. 1 that I could reach confirm the pleading content (NDA No. 208109; '724, '981, '218, '980, '905) but not the page-14 signature block. Because the docket has no separate appearance entries, the signatories of D.I. 1 are the operative counsel of record — I am confident Morris Nichols (Jacobs, and almost certainly Blumenfeld/Noreika) plus Paul Hastings of counsel signed it, but I did not see the block itself. Anyone needing a courtroom-grade citation should pull D.I. 1 at p. 13–14.
• No in-house counsel appears anywhere in the record; Helsinn Therapeutics (U.S.), Inc. was not a party and no corporate counsel signature appears.
• Nothing is sealed in this case — it simply never got past the pleading stage. Docket note: the complaint was filed as 1:15-cv-00918-UNA (unassigned) with a magistrate consent notice, and was assigned to Judge Gregory M. Sleet; termination date is docketed as 12/01/2015 (FJC lists Dec. 2, 2015).

Why this roster matters (strategic read)

The near-identical plaintiff team — Morris Nichols in Wilmington, O'Malley/Dittmann's Paul Hastings group as merits counsel, with Loeb & Loeb for Roche — was rolled out in the D.N.J. refilings (Nos. 15-7015 and 15-7378 against Fresenius/Exela, filed Sept.–Oct. 2015, with Saul Ewing as New Jersey local counsel). Helsinn's D. Del. and D.N.J. palonosetron campaign was prosecuted by the same small, stable core group across roughly a dozen ANDA/505(b)(2) defendants, which is why the 00918 dismissal produced no new appearances: the same Delaware counsel who signed the dismissal simply continued in the New Jersey cases.

Sources: CourtListener docket 4220932 (D. Del. 1:15-cv-00918), including D.I. 1 (filed 10/13/2015) and the 12/01/2015 voluntary dismissal; CourtListener docket 4220916 (1:15-cv-00865) parties page; CourtListener RECAP PDFs from C.A. No. 13-688-GMS (D.I. 99, 159) showing the Morris Nichols/Paul Hastings plaintiffs' blocks; D.N.J. No. 15-7015 D.I. 14 and No. 15-7378 D.I. 11 signature blocks (Saul Ewing; Paul Hastings; Loeb & Loeb); UniCourt docket summary for 1:15-cv-00865; DrugPatentWatch litigation page for 1:15-cv-00918; Chambers profile of Karen Jacobs.

I'll research the docket and counsel of record for Fresenius Kabi in this D. Del. action.

Let me pull the actual docket sheet for 1:15-cv-00918.

Bottom line

No attorney ever entered an appearance for Fresenius Kabi USA, LLC in D. Del. No. 1:15-cv-00918. The case was on file for only seven weeks and was dismissed before issue was joined, so there is no defense "counsel of record" in this docket to identify. Anyone who tells you a specific firm was "of record" for Fresenius in this case is inferring, not reporting a docket entry.

What the docket actually shows

The PACER/RECAP docket as mirrored on CourtListener (docket no. 4220932) contains only eight entries, all filed by the court or by plaintiffs:

Corroborating the absence of any defense participation: the FJC Integrated Database record for this docket (via CourtListener's IDB page) lists "Procedural Progress: No court action (before issue joined)" and "No court action" — i.e., no answer, no Rule 12 motion, no appearance. There is no answer, no motion to dismiss, no extension request, and no stipulation in the docket.

Why: Fresenius's palonosetron dispute was being litigated in New Jersey, where Helsinn had already sued on 9/22–9/23/2015 (D.N.J. 3:15-cv-07015, later consolidated with 3:15-cv-02077 and 3:15-cv-07378). Plaintiffs filed this Delaware case on the newer NDA No. 208109 patents ('980 and '905 had just issued) and then pulled it — the practical effect being that Fresenius never had to appear in Delaware on this NDA.

Who actually represented Fresenius Kabi in the refiled/parallel litigation

These are not counsel of record in 1:15-cv-00918, but they are the attorneys who represented the same defendant on the same NDA and patents in the New Jersey actions that subsumed this case, and are the best documentary answer to "who defended Fresenius here":

• Karen A. Confoy — local counsel (New Jersey). Fox Rothschild LLP, 997 Lenox Drive, Building 3, Lawrenceville, NJ. She signed Fresenius Kabi's Answer, Affirmative Defenses and Counterclaims expressly "Attorneys for Fresenius Kabi USA, LLC" in Helsinn Healthcare S.A. v. Fresenius Kabi USA, LLC, No. 3:15-cv-07378 (MLC)(DEA), D.I. 11 — the consolidated palonosetron action covering the same five patents ('724, '981, '218, '980, '905) and the same NDA No. 208109. Fox Rothschild is a frequent Hatch-Waxman defense firm; I have not independently sourced a fuller case list for her.
• Schiff Hardin LLP (Chicago) — lead/coordinating counsel for Fresenius Kabi in the consolidated New Jersey palonosetron actions. A joint status letter in the consolidated cases (D.N.J. 15-2077 / 15-7015 / 15-7378, D.I. 68) states that the writer "together with Schiff Hardin LLP represent Fresenius Kabi USA, LLC." I could not verify from the available materials which individual Schiff Hardin attorneys signed that letter or appeared pro hac vice, so I am not naming them. (Note: Schiff Hardin combined with ArentFox Schiff in 2022.)
• Potter Anderson & Corroon LLP (Wilmington, DE) — Richard L. Horowitz, David E. Moore, Bindu A. Palapura — represented Fresenius Kabi in other Delaware Hatch-Waxman matters in the same period (e.g., Millennium Pharmaceuticals v. Fresenius Kabi, C.A. No. 13-467 (GMS), and the consolidated C.A. No. 12-1011 (GMS)). This is a pattern of Delaware counsel, not a docket fact in 1:15-cv-00918; no appearance by them exists in this case.

For completeness — plaintiffs' side (the only appearances in the docket)

• Morris, Nichols, Arsht & Tunnell LLP, Wilmington, DE: Jack B. Blumenfeld, Maryellen Noreika, Karen Jacobs (Jacobs signed the dismissal).
• Paul Hastings LLP, New York (of counsel): Joseph M. O'Malley, Jr., Eric W. Dittmann, Isaac S. Ashkenazi, Gary Ji, Angela C. Ni, Dana Weir (in some iterations Bruce M. Wexler and David M. Conca).
• Loeb & Loeb LLP, New York (of counsel for Roche Palo Alto): Mark E. Waddell.

Caveats on sourcing

• The docket image set I relied on is the CourtListener RECAP mirror, which shows no document between D.I. 5 and D.I. 7. If a sealed appearance or an unfiled-but-served courtesy copy of an answer exists, it would not appear there — but the FJC "before issue joined" flag independently indicates nothing was filed by the defense.
• Parallel D. Del. No. 1:15-cv-00865 (Helsinn v. Fresenius Kabi, filed 9/24/2015, ANDA No. 206802, patents '724, '725, '424, '219, '094) is a different case involving the same parties; I did not verify whether defense counsel appeared there, and it should not be conflated with 00918.
• To close the remaining gap, the definitive sources would be: (1) PACER for D. Del. 1:15-cv-00918 (confirm the absence of any appearance); (2) the D.N.J. consolidated docket 3:15-cv-07378 for the full pro hac vice admission list (Schiff Hardin attorneys) and the appearance list for 3:15-cv-07015; and (3) Fox Rothschild's and Schiff Hardin/ArentFox Schiff's attorney biographies for Confoy and the Schiff Hardin team.